Glaukos Corporation (NYSE:GKOS) Files An 8-K Entry into a Material Definitive Agreement


Glaukos Corporation (NYSE:GKOS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

On November 14, 2018, Glaukos Corporation (the “Company”) entered into an Office Building Lease dated as of November 14, 2018 (the “Lease”), between the Company and CIP 2014/SG, Aliso Owner LLC (“Landlord”), to which the Company will lease three existing office buildings, comprising approximately 160,000 rentable square feet of space, located in Aliso Viejo, California (the “Aliso Facility”). The term of the Lease will commence on May 1, 2019 and continue for 13 years. The Company intends to relocate its corporate administrative headquarters, along with certain laboratory, R&D and warehouse space, to the Aliso Facility. The Company currently intends to maintain its manufacturing facilities at its San Clemente location for the foreseeable future.

Under the terms of the Lease, the Company’s rent will be abated for 16 months.The Company will also receive an allowance from the Landlord to be applied to the Company’s construction of tenant improvements at the Aliso Facility following the commencement date of the Lease.The effectiveness of this Lease is contingent upon the Company’s purchase of certain undeveloped land located adjacent to the Aliso Facility.

The description above of the terms of the Lease is subject in its entirety to the terms of the Lease, which will be attached as an exhibit to the Company’s Annual Report on Form 10-K that will be filed with the U.S. Securities and Exchange Commission for the year ending December 31, 2018.

Item 7.01. Regulation FD Disclosure.

Glaukos Corporation (the “Company”) intends to present the materials attached as Exhibit 99.1 to this Current Report on Form 8-K (the “Investor Presentation”) from time to time in presentations to investors and other stakeholders. The Investor Presentation will also be available on the investor page of the Company’s website at

The information contained in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing of the Company whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.



Investor Presentation, dated November 2018

GLAUKOS Corp Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 Exhibit 99.11 © 2018 Glaukos Corporation 1 November 20182 © 2018 Glaukos Corporation All statements other than statements of historical facts included in this presentation that address activities,…
To view the full exhibit click here

About Glaukos Corporation (NYSE:GKOS)

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a corneal incision. The Company’s micro-scale injectable therapies include pipeline products, such as the iStent Inject, the iStent Supra and iDose. The iStent Inject includes approximately two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.